2020
Effect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2019
Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database
Byrne RM, Gilbert EW, Dewey EN, Herzig DO, Lu KC, Billingsley KG, Deveney KE, Tsikitis VL. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database. Journal Of Surgical Research 2019, 238: 198-206. PMID: 30772678, DOI: 10.1016/j.jss.2019.01.039.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAppendiceal NeoplasmsChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesSex FactorsTreatment OutcomeUnited StatesConceptsPerioperative intraperitoneal chemotherapyAppendiceal cancerCytoreductive surgeryIntraperitoneal chemotherapyTreatment modalitiesNational Cancer Database dataMultivariate logistic regression analysisNational Cancer DatabasePatterns of careLow-grade tumorsNon-Hispanic ethnicityLogistic regression analysisMucinous malignanciesSystemic chemotherapyMultimodality treatmentClinical factorsImproved survivalPatient selectionMale sexKaplan-MeierPatient cohortCancer DatabaseWhite raceTreatment groupsChemotherapy
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3
2010
Adjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2008
Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer
Morris A, Billingsley K, Hayanga A, Matthews B, Baldwin L, Birkmeyer J. Response: Re: Residual Treatment Disparities After Oncology Referral for Rectal Cancer. Journal Of The National Cancer Institute 2008, 100: 1740-1740. PMID: 18477800, PMCID: PMC2766763, DOI: 10.1093/jnci/djn396.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantConfidence IntervalsDecision MakingFemaleHealth Services AccessibilityHealthcare DisparitiesHumansLogistic ModelsMaleMedical OncologyMedical Record LinkageMedicareNeoplasm StagingPractice Patterns, Physicians'Radiation OncologyRadiotherapy, AdjuvantRectal NeoplasmsReferral and ConsultationSEER ProgramUnited StatesWhite PeopleConceptsRectal cancerAdjuvant therapyBlack patientsWhite patientsRadiation oncologistsAdjuvant treatmentMedical oncologistsEnd Results-Medicare dataProvider decision makingPatient-provider interactionsFrequency of consultationsLow treatment ratesClinical characteristicsElderly patientsConsultation ratesOncology referralTreatment disparitiesPatient preferencesProvider characteristicsRadiation therapyPatientsOncologistsTherapyStage IITreatment ratesSurvival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Dobie S, Warren J, Matthews B, Schwartz D, Baldwin L, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112: 789-799. PMID: 18189291, PMCID: PMC3103394, DOI: 10.1002/cncr.23244.Peer-Reviewed Original ResearchConceptsStage II patientsRectal cancer patientsStage III patientsII patientsCancer patientsStage IIAdjuvant radiationAdjuvant therapyIII patientsGeneral populationStage II rectal cancer patientsLower cancer-related mortalityReceipt of chemoradiationCancer mortality riskCancer-related mortalityMultivariate logistic regressionAdjusted riskAdjuvant chemoradiationChemotherapy receiptSurgical resectionSurvival benefitSEER-MedicareTherapy adherencePatient groupRadiation therapy
2006
Completion of Therapy by Medicare Patients With Stage III Colon Cancer
Dobie S, Baldwin L, Dominitz J, Matthews B, Billingsley K, Barlow W. Completion of Therapy by Medicare Patients With Stage III Colon Cancer. Journal Of The National Cancer Institute 2006, 98: 610-619. PMID: 16670386, PMCID: PMC3124351, DOI: 10.1093/jnci/djj159.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColonic NeoplasmsFemaleFrail ElderlyHumansLogistic ModelsMaleMedicareNeoplasm StagingPatient CompliancePredictive Value of TestsReproducibility of ResultsRisk FactorsSEER ProgramSocial SupportUnited StatesConceptsStage III colon cancerCompletion of therapyAdjuvant chemotherapyAdjuvant therapyChemotherapy completionPhysician characteristicsMedicare claimsColon cancerStage III colon cancer patientsEnd Results program dataMultivariable logistic regression modelingAdjuvant chemotherapy completionChemotherapy completion rateIncomplete adjuvant chemotherapySEER program dataColon cancer resectionCancer-related mortalityPredictors of initiationColon cancer patientsLogistic regression modelingProgram dataPatient characteristicsCancer resectionTreatment complicationsCancer mortality
2005
Explaining Black–White Differences in Receipt of Recommended Colon Cancer Treatment
Baldwin L, Dobie S, Billingsley K, Cai Y, Wright G, Dominitz J, Barlow W, Warren J, Taplin S. Explaining Black–White Differences in Receipt of Recommended Colon Cancer Treatment. Journal Of The National Cancer Institute 2005, 97: 1211-1220. PMID: 16106026, PMCID: PMC3138542, DOI: 10.1093/jnci/dji241.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanChemotherapy, AdjuvantCohort StudiesColonic NeoplasmsComorbidityFemaleHealth Services AccessibilityHumansLength of StayMaleMedicareOdds RatioPractice Patterns, Physicians'Retrospective StudiesRisk FactorsSEER ProgramSeverity of Illness IndexSocial SupportSocioeconomic FactorsUnited StatesWhite PeopleConceptsHealth system factorsBlack-White disparitiesChemotherapy receiptWhite patientsMedical oncologistsBlack patientsCancer treatmentRetrospective cohort studyBlack-white differencesColon cancer resectionAmerican Medical Association MasterfileEnd Results ProgramColorectal cancer treatmentColon cancer careColon cancer patientsLogistic regression analysisSystem factorsRegression analysisNeighborhood socioeconomic statusColon cancer treatmentAdjuvant chemotherapyChemotherapy useCohort studyCancer resectionIllness severity
2002
Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia
Dominitz J, Maynard C, Billingsley K, Boyko E. Race, Treatment, and Survival of Veterans With Cancer of the Distal Esophagus and Gastric Cardia. Medical Care 2002, 40: i-14. PMID: 11789626, DOI: 10.1097/00005650-200201001-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBlack or African AmericanCarcinoma, Squamous CellCardiaChemotherapy, AdjuvantCohort StudiesEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionHealth Services AccessibilityHealth Services ResearchHospitals, VeteransHumansMaleProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisUnited StatesVeteransWhite PeopleConceptsSquamous cell carcinomaDistal esophageal cancerSurgical resectionBlack patientsRadiation therapyEsophageal cancerEsophageal adenocarcinomaEqual‐access medical systemWhite veteransVeterans Affairs Medical CenterBlack male veteransDistal esophageal adenocarcinomaSurvival of veteransRetrospective cohort studySurvival of patientsCohort studyGastric cardiaDistal esophagusSimilar oddsCell carcinomaCancer survivalMedical CenterInvasive proceduresLower oddsSimilar survival